Financials in USD. Standardized financial statements.
A compact view of how DMK Pharmaceuticals Corporation turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Revenue? | $4.76M | $2.21M | $2.78M | $22.11M | $15.09M | $13.07M | $6.47M |
| Revenue Growth? | +115.3% | -20.5% | -87.4% | +46.6% | +15.4% | +101.9% | 0.0% |
| Cost of Revenue? | $7.65M | $6.87M | $6.33M | $15.68M | $12.90M | $10.48M | $7.39M |
| Gross Profit? | -$2.90M | -$4.66M | -$3.55M | $6.44M | $2.19M | $2.59M | -$914,314 |
| Gross Margin? | -60.9% | -211.1% | -127.9% | +29.1% | +14.5% | +19.8% | -14.1% |
| Operating Expenses? | $22.16M | $27.41M | $28.13M | $36.44M | $42.54M | $27.28M | $24.29M |
| Operating Income? | -$25.06M | -$32.07M | -$31.68M | -$30.00M | -$40.35M | -$24.69M | -$25.20M |
| EBITDA? | -$23.58M | -$30.63M | -$33.51M | -$25.07M | -$37.02M | -$22.58M | -$21.26M |
| Income Before Tax | -$26.20M | -$34.60M | -$35.84M | -$28.16M | -$40.28M | -$25.88M | -$24.01M |
| Income Tax Expense | $2,000 | $796 | $2,400 | -$643,328 | -$1.27M | -$339,391 | -$4.57M |
| Net Income? | -$26.48M | -$45.83M | -$49.39M | -$27.51M | -$39.01M | -$25.54M | -$19.44M |
| EPS? | $-12.37 | $-22.25 | $-44.57 | $-36.16 | $-69.86 | $-63.06 | $-77.75 |
| Diluted EPS? | $-12.37 | $-22.25 | $-44.57 | $-36.16 | $-69.86 | $-63.06 | $-77.75 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality